Auranofin, a former drug used for polyarthritis, has been studied for its potential antibiotic use. Despite its described effect on several pathogens, its impact on commensal bacteria reminds unknown.
The impact on the resident bacteria of the gut is a key component of antibiotics, especially in the context of infection by Clostridioides difficile. In fact, the microbiota prevents C. difficile infection and protects for relapse. Thus, a good anti-C. difficile treatment should have the smallest impact on the gut to have a low relapse-rate. In this project, we want to determine the impact of auranofin on the gut microbiota to place auranofin on the therapeutic arsenal against C. difficile.
